The novel coronavirus disease 2019(COVID-19)is the third coronavirus outbreak in the last two decades.Emerging and re-emerging infections like COVID-19 pose serious challenges of the paucity of information and lack of...The novel coronavirus disease 2019(COVID-19)is the third coronavirus outbreak in the last two decades.Emerging and re-emerging infections like COVID-19 pose serious challenges of the paucity of information and lack of specific cure or vaccines.This leaves utilisation of existing scientific data on related viral infections and repurposing relevant aetiologic and supportive therapies as the best control approach while novel strategies are developed and trialled.Many promising antiviral agents including lopinavir,ritonavir,remdesivir,umifenovir,darunavir,and oseltamivir have been repurposed and are currently trialled for the care for COVID-19 patients.Adjunct therapies for the management of symptoms and to provide support especially in severe and critically ill patients have also been identified.This review provides an appraisal of the current evidence for the rational use of frontline therapeutics in the management of COVID-19.It also includes updates regarding COVID-19 immunotherapy and vaccine development.展开更多
Severe acute respiratory syndrome coronavirus-2 infection is usually self-limited,with a short duration for viral shedding within several weeks.However,prolonged viral shedding has been observed in severe or immune-co...Severe acute respiratory syndrome coronavirus-2 infection is usually self-limited,with a short duration for viral shedding within several weeks.However,prolonged viral shedding has been observed in severe or immune-compromised coronavirus disease 2019(COVID-19)cases.Here,we reported that three young adult cases of COVID-19 patients,who were either immunosuppressed nor severe,showed prolonged viral RNA shedding from the upper respiratory tract for 58,81,and 137 days since initial diagnosis.To our knowledge,this is the longest duration of viral shedding reported to date in young adult patients.Further studies on factors relevant to prolonged viral positivity,as well as the correlation between viral positivity and transmission risk are needed for the optimal management of COVID-19 patients with prolonged nucleic acid positive.展开更多
We present an example of applying'need-driven'product design principle to the development of a rapid test kit to detect SARS-COV-2(COVID-19).The tests are intended for use in the field and,longer term,for home...We present an example of applying'need-driven'product design principle to the development of a rapid test kit to detect SARS-COV-2(COVID-19).The tests are intended for use in the field and,longer term,for home use.They detect whether a subject is currently infected with the virus and is infectious.The urgent need for large numbers of tests in field setting imposes constraints such as short test time and lack of access to specialist equipment,laboratories and skilled technicians to perform the test and interpret results.To meet these needs,an antigen test based on RT-LAMP with colorimetric readout was chosen.Direct use of swab sample with no RNA extraction was explored.After extensive experimental study(reported elsewhere),a rapid test kit has been fabricated to satisfy all design criteria.展开更多
文摘The novel coronavirus disease 2019(COVID-19)is the third coronavirus outbreak in the last two decades.Emerging and re-emerging infections like COVID-19 pose serious challenges of the paucity of information and lack of specific cure or vaccines.This leaves utilisation of existing scientific data on related viral infections and repurposing relevant aetiologic and supportive therapies as the best control approach while novel strategies are developed and trialled.Many promising antiviral agents including lopinavir,ritonavir,remdesivir,umifenovir,darunavir,and oseltamivir have been repurposed and are currently trialled for the care for COVID-19 patients.Adjunct therapies for the management of symptoms and to provide support especially in severe and critically ill patients have also been identified.This review provides an appraisal of the current evidence for the rational use of frontline therapeutics in the management of COVID-19.It also includes updates regarding COVID-19 immunotherapy and vaccine development.
基金supported by the Key Research and Development Program of Guangxi(AB20059001).
文摘Severe acute respiratory syndrome coronavirus-2 infection is usually self-limited,with a short duration for viral shedding within several weeks.However,prolonged viral shedding has been observed in severe or immune-compromised coronavirus disease 2019(COVID-19)cases.Here,we reported that three young adult cases of COVID-19 patients,who were either immunosuppressed nor severe,showed prolonged viral RNA shedding from the upper respiratory tract for 58,81,and 137 days since initial diagnosis.To our knowledge,this is the longest duration of viral shedding reported to date in young adult patients.Further studies on factors relevant to prolonged viral positivity,as well as the correlation between viral positivity and transmission risk are needed for the optimal management of COVID-19 patients with prolonged nucleic acid positive.
文摘We present an example of applying'need-driven'product design principle to the development of a rapid test kit to detect SARS-COV-2(COVID-19).The tests are intended for use in the field and,longer term,for home use.They detect whether a subject is currently infected with the virus and is infectious.The urgent need for large numbers of tests in field setting imposes constraints such as short test time and lack of access to specialist equipment,laboratories and skilled technicians to perform the test and interpret results.To meet these needs,an antigen test based on RT-LAMP with colorimetric readout was chosen.Direct use of swab sample with no RNA extraction was explored.After extensive experimental study(reported elsewhere),a rapid test kit has been fabricated to satisfy all design criteria.
